Chronic Myeloid Leukemia Coverage from Every Angle

Novel TKI Under Study in T315I-Mutated Chronic-Phase CML

By: Julia Fiederlein
Posted: Tuesday, January 5, 2021

According to Qian Jiang, MD, of Peking University People’s Hospital, Beijing, China, and colleagues, olverembatinib (HQP1351) seems to be safe and active in patients with T315I-mutated chronic-phase chronic myeloid leukemia (CML). The multicenter phase II HQP1351-CC201 trial results were presented during the virtual edition of the 2020 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 651).

“Olverembatinib is an orally active third-generation BCR-ABL tyrosine kinase inhibitor designed for the treatment of patients with CML harboring a T315I mutation,” the investigators commented. In this trial, a total of 41 patients with tyrosine kinase inhibitor (TKI)-resistant disease were administered 40 mg of olverembatinib once every other day for 28 consecutive days per cycle over 24 months. Follow-up data were provided for a median of 7.9 months.

The mean progression-free survival rates were 100.0% and 96.7% at 3 and 6 months, respectively. A total of 31 patients did not have a complete hematologic response at baseline; however, 96.8% of this population achieved a complete hematologic response after treatment. In the patients who did not have a complete cytogenetic response at baseline, a major cytogenetic response rate of 75.6% was observed; this included those with complete (65.9%) and partial (9.8%) cytogenetic responses. Major molecular responses occurred in 48.8% of patients.

Thrombocytopenia (all grades: 65.9%; grade 3 to 4: 48.8%), anemia (48.8%; 24.4%), leukopenia (46.3%; 12.2%), and neutropenia (36.6%; 19.5%) were among the most frequently reported treatment-related adverse events. The most common nonhematologic treatment-related adverse events were skin pigmentation (53.7%) and elevations in creatine kinase (48.8%), alanine transaminase (31.7%), and aspartate transaminase (26.8%). No treatment-related deaths were reported.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.